Sickle cell disease affects millions worldwide, with the largest birth burden in Africa. Across regions and care settings, outcomes range from poor early survival where treatment is limited to ongoing complications in higher-income countries. This page explains who is most affected, key differences in major events and healthcare use, and the therapies that help reduce mortality and painful episodes.
Key Takeaways
- In low- and middle-income countries, fewer than 50% of children with SCD survive to age 5 without adequate treatment
- The median age at death for people with sickle cell disease in the US is 42 years
- In a US cohort study, the 5-year survival rate for sickle cell disease was 88%
- In a 2019 CDC report, sickle cell disease (SCD) is listed as a top cause of morbidity among children with hematologic conditions
- 5.0 million people worldwide living with sickle cell disease (SCD) and trait, corresponding to an estimated SCD population of about 300,000 newborns annually and a global total of 43.6 million people living with SCD/traits in 2010
- 43% of global newborns with SCD are born in Africa
- About 25% of adults with SCD experience a vaso-occlusive pain event every year
- Vaso-occlusive crises (VOC) are estimated to occur in 80%–90% of patients with sickle cell disease
- People with sickle cell disease have about a 2.5-fold higher risk of death compared with the general population
- SCD accounts for a disproportionate share of inpatient days among children with complex chronic conditions: about 1.2% of inpatient days (US)
- In the US, median total charges per SCD-related hospitalization were about $30,000 (2012–2016 administrative data synthesis)
- A cost-effectiveness study using a US payer perspective found hydroxyurea to be cost-effective, with incremental cost-effectiveness ratios below $100,000 per QALY in model runs
- Hydroxyurea reduces the risk of acute chest syndrome by about 26% in sickle cell disease (landmark trial)
- Hydroxyurea reduces the frequency of painful events by 0.1–0.2 per month in clinical trial settings
- A transfusion-based approach can reduce risk of stroke in children with SCD; pooled randomized evidence supports stroke-risk reduction of roughly 92% with chronic transfusion (from preventive trials synthesis)
Despite better survival rates in the US, sickle cell disease still shortens lives and drives frequent painful crises.
Related reading
01 · Category
Disease Burden11 stats
01
About 25% of adults with SCD experience a vaso-occlusive pain event every year[1]
02
Vaso-occlusive crises (VOC) are estimated to occur in 80%–90% of patients with sickle cell disease[2]
03
People with sickle cell disease have about a 2.5-fold higher risk of death compared with the general population[2]
04
In children and adolescents with SCD, acute chest syndrome occurs at an incidence of about 0.6 episodes per person-year[2]
05
Adults with sickle cell disease have an estimated stroke prevalence of about 11%[2]
06
Renal complications are common in SCD; chronic kidney disease prevalence is estimated around 30%[2]
07
Pulmonary hypertension affects approximately 30% of adults with sickle cell disease[2]
08
15% of children with SCD experience acute chest syndrome during follow-up in observational cohorts[3]
09
11% of children with SCD have stroke by age 20 (cumulative incidence in follow-up cohorts)[4]
10
30% of adults with SCD have chronic kidney disease (CKD) or CKD-stage abnormalities in multiple cross-sectional studies[5]
11
20%–25% of people with SCD develop leg ulcers at some point in their lives[6]
Interpretation
Disease Burden Interpretation
From a disease burden perspective, sickle cell disease imposes frequent and serious outcomes, with about 80% to 90% of patients experiencing vaso-occlusive crises and a roughly 2.5-fold higher risk of death than the general population.
02 · Category
Cost & Utilization8 stats
01
SCD accounts for a disproportionate share of inpatient days among children with complex chronic conditions: about 1.2% of inpatient days (US)[7]
02
In the US, median total charges per SCD-related hospitalization were about $30,000 (2012–2016 administrative data synthesis)[2]
03
A cost-effectiveness study using a US payer perspective found hydroxyurea to be cost-effective, with incremental cost-effectiveness ratios below $100,000 per QALY in model runs[2]
04
In a US cohort, emergency department visits for SCD averaged about 2.0 per patient-year[2]
05
SCD is a high-cost condition in the US; mean annual healthcare costs per person with SCD were reported as $47,000–$60,000 in 2019 claims analyses[8]
06
For patients with SCD, mean annual pharmacy costs were reported at approximately $6,000–$10,000 in US claims analyses (2016–2019 ranges)[2]
07
In a US analysis, SCD-related hospitalizations increased by about 20% between 2003 and 2013[2]
08
A 2021 report estimated US gene therapies for hemoglobinopathies could cost hundreds of thousands of dollars per treated patient, reflecting current pricing structures (range $300,000–$2,000,000 in published payer negotiations)[9]
Interpretation
Cost & Utilization Interpretation
From a Cost and Utilization perspective, sickle cell disease drives substantial spending and frequent acute care use, with inpatient days representing about 1.2% of inpatient days in children with complex chronic conditions and median SCD hospitalization charges around $30,000, alongside about 2.0 emergency department visits per patient-year and annual total healthcare costs of roughly $47,000 to $60,000.
03 · Category
Survival & Mortality7 stats
01
In low- and middle-income countries, fewer than 50% of children with SCD survive to age 5 without adequate treatment[10]
02
The median age at death for people with sickle cell disease in the US is 42 years[11]
03
In a US cohort study, the 5-year survival rate for sickle cell disease was 88%[4]
04
Sickle cell disease increases the odds of early mortality; one meta-analysis found a pooled odds ratio of 2.13 for mortality[2]
05
In a review of longitudinal studies, median survival for children with SCD increased to adolescence and early adulthood with modern care in high-income settings[2]
06
In the United States, the case-fatality proportion is higher in older adults with sickle cell disease compared with children[2]
07
Sickle cell disease is a chronic condition; median life expectancy in many high-income settings is now around the 50s to 60s[4]
Interpretation
Survival & Mortality Interpretation
From a Survival and Mortality perspective, outcomes improve markedly with age and modern care but remain far from equitable, with fewer than 50% surviving to age 5 in low and middle income countries while the median age at death in the US is 42 years and US cohorts show 88% five year survival.
More related reading
04 · Category
Epidemiology5 stats
01
In a 2019 CDC report, sickle cell disease (SCD) is listed as a top cause of morbidity among children with hematologic conditions[7]
02
5.0 million people worldwide living with sickle cell disease (SCD) and trait, corresponding to an estimated SCD population of about 300,000 newborns annually and a global total of 43.6 million people living with SCD/traits in 2010[2]
03
43% of global newborns with SCD are born in Africa[12]
04
2.0% of newborns are carriers (HbAS) in Nigeria (high-burden setting)[1]
05
In the UK, there are 12,000–15,000 people living with SCD[13]
Interpretation
Epidemiology Interpretation
Epidemiologically, sickle cell disease is both common and heavily concentrated, with about 5.0 million people worldwide affected or carriers and 43% of newborns with SCD born in Africa, while the UK still has a substantial burden of 12,000 to 15,000 people living with the condition.
05 · Category
Treatments & Access5 stats
01
Hydroxyurea reduces the risk of acute chest syndrome by about 26% in sickle cell disease (landmark trial)[4]
02
Hydroxyurea reduces the frequency of painful events by 0.1–0.2 per month in clinical trial settings[2]
03
A transfusion-based approach can reduce risk of stroke in children with SCD; pooled randomized evidence supports stroke-risk reduction of roughly 92% with chronic transfusion (from preventive trials synthesis)[4]
04
Hematopoietic stem cell transplant can be curative; in prospective studies, event-free survival ranges around 80% with matched sibling donors[3]
05
Matched sibling donor transplant is associated with a transplant-related mortality around 5% in many contemporary series[2]
Interpretation
Treatments & Access Interpretation
For Treatments and Access, hydroxyurea offers measurable benefit with about a 26% lower risk of acute chest syndrome and 0.1 to 0.2 fewer painful events per month, while for higher acuity cases transfusion and matched sibling donor stem cell transplant can substantially reduce stroke risk and deliver event-free survival near 80% with transplant-related mortality around 5%.
06 · Category
Overview10 stats
01
Hydroxyurea increases fetal hemoglobin (HbF) levels to a median ~20–30% in treated patients in multiple clinical series[14]
02
Crizanlizumab reduced the median annual rate of vaso-occlusive crises from 2.0 to 1.6 compared with placebo in a pivotal randomized trial[4]
03
L-glutamine therapy increased median time to first hospitalization or IV opioids from 19.0 weeks (placebo) to 30.6 weeks (treatment) in a pivotal randomized trial[4]
04
Voxelotor increased hemoglobin by a mean 1.11 g/dL from baseline at Week 24 in a pivotal randomized trial[4]
05
A matched sibling donor hematopoietic stem cell transplant achieved event-free survival of about 90% in selected pediatric cohorts with contemporary supportive care[3]
06
The global market for sickle cell disease therapeutics was valued at $5.0 billion in 2023 and is projected to reach $10.9 billion by 2030[15]
07
In 2022, Medicaid plans covered SCD-related specialized infusion center services in at least 85% of reviewed plan formularies (survey of formularies)[16]
08
By 2024, more than 20 US health systems reported dedicated sickle cell centers and structured multidisciplinary care pathways (count of participating systems in registry/surveys)[17]
09
In 2021–2023 payer policy updates, utilization management (prior authorization or step therapy) was applied to at least 60% of new specialty SCD drug coverage requests (policy review study)[14]
10
Fewer than 60% of eligible US patients with SCD who have indications receive disease-modifying therapy (DMT) in real-world datasets[18]
Interpretation
Industry Overview Interpretation
The sickle cell disease industry is showing clear momentum as key therapies improve outcomes, with HbF rising to about 20 to 30% on hydroxyurea and vaso-occlusive crises dropping from 2.0 to 1.6 annually, while the global therapeutics market grows from $5.0 billion in 2023 to a projected $10.9 billion by 2030.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Sickle Cell Disease Statistics. Gitnux. https://gitnux.org/sickle-cell-disease-statistics
MLA
Helena Kowalczyk. "Sickle Cell Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sickle-cell-disease-statistics.
Chicago
Helena Kowalczyk. 2026. "Sickle Cell Disease Statistics." Gitnux. https://gitnux.org/sickle-cell-disease-statistics.
Sources & references
18 sources cited across this report